Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital
|
|
- Robyn Reynolds
- 5 years ago
- Views:
Transcription
1 Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital August 28, 2018 Hosted by John A. Renner, Jr., MD, DLFAPA Professor of Psychiatry Boston University School of Medicine Director, Addiction Psychiatry Residency Training Boston University Medical Center and VA Boston Healthcare System 1
2 Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital Christopher Welsh, MD University of Maryland School of Medicine August 28,
3 Learning Objectives 1. Learners will distinguish the role that hospitals can have in providing medication to treat opioid use disorder. 2. Learners will summarize the exceptions to federal laws that allow medication to be provided to patients in the emergency department and hospital. 3. Learners will analyze hospital-based initiatives to treat opioid use disorder in various parts of the United States. 3
4 Contents Epidemiology History of treatment of Opioid Use Disorder The Law & Opioids OUD in the Hospital Psychiatric Inpatient -Consult Liaison Emergency Department -Psychiatric ED Education on OUD
5 Confusing Terms Addiction Dependence Use Misuse Abuse Risky/At-risk Use Problematic Use Non-medical Use Non-prescribed Use Illicit Use Illicit Use of a Licit Substance Experimentation
6 JUNKIE DRUGGIE Dope Fiend DRUNK Other Terms ADDICT Alchie WINO LOSER SWAF shooter Dirty
7
8
9
10 ORP Training of Trainers
11
12
13 NATIONAL RATE OF OPIOID-RELATED INPATIENT STAYS AND EMERGENCY DEPARTMENT VISITS,
14 RATE OF OPIOID-RELATED EMERGENCY DEPARTMENT VISITS BY STATE, 2014 RATE OF OPIOID-RELATED INPATIENT STAYS BY STATE, 2014
15 ADDICTION IS TREATABLE!!!
16 Maintenance Medications For OUD FDA Approved Methadone (Methadose; Dolophine) Buprenorphine(Suboxone; Suboxone Film; Subutex; Bunavail; Zubsolv; Sublocade) Naltrexone (Trexan; Vivitrol) Experimental/Not Approved Ibogaine Heroin Hydromorphone
17 I received a note from her when she had used this. She was much encouraged and had ordered two pounds more I saw her recently when she assured me that she had no desire for morphine. Dr. W.H. Bentley Detroit Therapeutic Gazette, 1880 (about a woman for whom he had prescribed one pound of cocaine for morphine addiction)
18 1904
19
20 The Harrison Narcotics Act (1914)
21 The shallow pretense that drug addiction is a disease which the specialist must be allowed to treat, which pretended treatment consists of supplying victims with the drug has caused their physical and moral debauchery American Medical Association Report of the Committee on the Narcotic Drug Situation, 1920
22
23
24
25 Opioids and the Law Comprehensive Drug Abuse Prevention & Control Act of 1970 (Controlled Substances Act) (1970) Narcotic Addict Treatment Act (1974) Drug Addiction Treatment Act of 2000 (DATA 2000) Comprehensive Addiction & Recovery Act (CARA)(2016)
26 Comprehensive Drug Abuse Prevention and Control Act of 1970 Controlled Substances Act Effectively replaced all previous laws dealing with narcotic /dangerous drugs Established a commission on marijuana and substance use disorders. Divided drugs into 5 schedules
27 Comprehensive Drug Abuse Prevention and Control Act of 1970 Generally, there are 2 requirements that a practitioner must meet if they wish to administer or dispense directly a narcotic drug listed in any schedule to a narcotic dependent person for the purpose of maintenance or detoxification treatment.. 1. Practitioner must be separately registered with the DEA as a narcotic treatment program. 2. Practitioner must be in compliance with DEA regulations, including those for treatment qualifications, security, records, and unsupervised use of the drugs 2 exceptions
28 Relief of Acute Withdrawal Exception The 3-day rule provides an exception to the CSA. Title 21 C.F.R allows a physician to administer (but not prescribe) narcotic drugs to a person for the purpose of relieving acute withdrawal symptoms when necessary while arrangements are being made for referral for treatment. However, the prescriber may not administer more than one day s medication at one time and such treatment may not last for more than 3 days; no renewals or extensions of that period are permitted. Applies in out-patient and Emergency Department settings
29 Incidental Adjunct Exception The adjunct rule provides an exception to the CSA. Title 21 C.F.R allows a physician or authorized hospital staff to administer or dispense narcotic drugs in a hospital to maintain or detoxify a person as an incidental adjunct to medical or surgical treatment of conditions other than addiction, or to administer or dispense narcotic drugs to persons with intractable pain in which no relief or cure is possible or none has been found after reasonable efforts. Unclear if this applies in the Emergency Department setting Generally does not apply in sub-acute hospital setting
30 Narcotic Addict Treatment Act (1974) Primarily spells out requirements for methadone programs Added a provision for Use of narcotic drugs in hospitals : For hospitalized patients, the use of a narcotic drug for narcotic addict treatment may be administered or dispensed only for detoxification treatment. If a narcotic drug is administered for treatment of narcotic dependence for more than 180 days, the procedure is no longer considered detoxification but is, rather, considered maintenance treatment...this does not preclude the maintenance treatment of a patient who is hospitalized for treatment of medical conditions other than addiction and who requires temporary maintenance treatment during critical period of his or her stay or whose enrollment in a program which has approval for maintenance treatment using narcotic drugs has been verified.
31 Narcotic Addict Treatment Act (1974) Any hospital which already has received approval under this paragraph may serve as a temporary narcotic treatment program when an approved treatment program has been terminated and there is no other facility immediately available in the area to provide narcotic drug treatment for the patients.
32 Drug Abuse Treatment Act Of 2000 Section 3502 of The Children s Health Act of 2000 Schedule III, IV, and V medications* (Buprenorphine) approved for detoxification and maintenance Allows: physicians to prescribe (in office-based setting) & pharmacists to dispense narcotics, specifically buprenorphine, to treat opioid addiction *does not apply to methadone or other opioids that are Schedule II
33 Comprehensive Addiction & Recovery Act (CARA) 2016 Allows: Nurse practitioners and physicians assistants to prescribe buprenorphine (requires extra training) Allows certified addiction specialists to treat 275 patients at a time (with extra reporting requirements)
34 Full Agonist Activity Levels Full Agonist (e.g. heroin) % Mu Receptor Intrinsic Activity Increasing full agonist dose produces increasing mu opioid receptor specific activity 0 no drug low dose high dose DRUG DOSE
35 Partial Agonist Activity Levels Full Agonist (e.g. heroin) % Mu Receptor Intrinsic Activity But due to its ceiling maximum opioid agonist effect is never achieved Partial Agonist (e.g. buprenorphine) no drug low dose Like full agonists, partial agonist drugs produce increasing mu opioid receptor specific activity at lower doses DRUG DOSE high dose
36 Antagonist Activity Levels % Mu Receptor Intrinsic Activity no drug low dose DRUG DOSE Opioid antagonists bind and occupy opioid receptors but result in no specific intrinsic activity regardless of dose Antagonist (e.g. naloxone) high dose
37
38
39 Opioid Use Disorder Management Applied Across Different Hospital Settings
40 Psychiatric Inpatient Unit Substance use disorders are DSM identified disorders, however, patients do not typically meet criteria for inpatient psychiatry units for SUD alone Varies by state Many patients have co-morbid SUD with their other psychiatric illnesses
41 Ψ Inpt Case Vignette BT is a 57 yo CM with hx of MDD and OUD, admitted to psychiatry after a suicide attempt by overdose on heroin/fentanyl (patient had some hypoxic brain injury). Patient was treated with SSRIs and underwent ECT. He agreed to MAT and was started on Suboxone, titrated to 12mg daily. Aftercare placement was very difficult. After several weeks, he was accepted at a recovery house program but they did not accept patient s on suboxone. He underwent a suboxone taper prior to discharge.
42 NALTREXONE
43 Ψ Inpt Case Vignette RM is a 50 y.o. male with hx of Schizophrenia admitted for worsening psychosis. Also with hx of heroin use disorder; on methadone 100mg daily His Quetiapine is increased over several days from 300mg to 600mg qhs Begins to experience lightheadedness, palpitations and has an episode of syncope QTc is found to be 580msec
44 Psychiatric Consult Liaison/ Non-Psych Hospitalization Identifying patients with opioid use disorder can be an initial barrier to care. Identifying withdrawal Clinical Opioid Withdrawal Scale, the Subjective Opioid Withdrawal Scale and the Objective Opioid Withdrawal Scale. Choosing how to treat withdrawal should consider The patient s preference for MAT Potential adverse effects ( QTc prolongation; drug-drug interaction) Availability for follow-up Initiation of opioid agonist therapy during an acute hospital admission reduces AMA discharges and increases chances of transition to long-term outpatient addiction treatment.
45
46 Hospital Buprenorphine Induction 220 patients enrolled 38% remained in treatment for 1 month, 17% for > 3 months During the year following enrollment compared to the year prior to enrollment: ED visits decreased by 23% Hospitalizations decreased by 45%
47 Psychiatric Consult Liaison/ Non-Psych Hospitalization Pain Management If the patient s future plans include buprenorphine Short acting opioids alone Buprenorphine +/- short acting (given buprenorphine's high affinity it mostly blocks other opioids) Split Buprenorphine to TID If patient s future plans include methadone maintenance Initiate methadone (or cont if already on) +/- additional short-acting opioids titrated to pain. Split the patient s daily methadone dose into TID
48 Buprenorphine & Pain In-patient the CSA exception allows any opioid to be used. Out-patient The formulations FDA approved for treatment of OUD can be used off label for the management of pain. The formulations FDA approved for treatment of pain can not be used to treat OUD (per DATA 2000)
49 CL Case Vignette #1 CJ is a 28yo female with a hx of opioid use d/o, and cocaine use d/o who presents to the ED with chest pain, fever and chills. She reports she speedballs around $100/day and has for past 4-5 years. In this time she has not had more than a day of abstinence and experiences significant withdrawal symptoms. She has never been on maintenance treatment. Her last use of heroin was minutes before coming to the hospital. She is found to have bacterial endocarditis and is being admitted to the hospital for 6 weeks of IV antibiotics. She will likely go to a sub-acute nursing facility (SNF)
50 SNFs AKA: Sub-acute Nursing Facilities Skilled Nursing Facilities Long-term Care Facilities Nursing homes rehabs (not the SUD treatment kind) SNFs traditionally do not fall under the adjunct exception. Murky DEA status
51 CL Case Vignette #2 54 y.o. female Admitted to hospital for pneumonia No significant Medical Hx; denies other meds Reports being on methadone 40mg/day for past 3 years; receives 13 take-homes Clinic is called and confirms the dose & that patient received 13 take-homes 3 days prior Medical team starts patient on 40mg/day Following day, patient is sedated with slowed respirations & constricted pupils
52
53 Emergency Department SBIRT alone is not generally effective for drugs need a treatment approach that utilizes early initiation of pharmacotherapy in combination with psychosocial approaches. ED initiated buprenorphine treatment can result in significantly decreased opioid use, increased engagement in outpatient substance abuse treatment, and decreased use of inpatient addiction services. Several Models
54 Yale ED-Initiated Bup Study 3 Groups ED-initiated buprenorphine (BUP) w/ 3-day prescription and referral to primary care buprenorphine provider Brief intervention (BI) and facilitated referral to drug treatment Simple referral (REF) to drug treatment Engagement in treatment at 30 days BUP Group 78%* BI Group 45% REF Group 37% Self-Reported Illicit Opioid Use (days per week) BUP Group 5.4 to 0.9* BI Group 5.6 to 2.4 REF Group 5.4 to 2.3 Urine Toxicology Negative for Opioids at 30 days BUP Group 58% BI Group 43% REF Group 54% *statistically significant D Onofrio, et al. JAMA; (16):
55 ED-Initiated Buprenorphine Baltimore City (2/17-4/18) Buprenorphine Data Elements Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Hospital 6 Hospital 7 Total Number of months using buprenorphine protocol Number of candidates identified in ED Number of patients receiving buprenorphine & referred to treatment Number of patients who entered outpatient treatment 9 (52.9%) 10 (55.6%) 10 (62.5%) 8 (505) 92 (57.5%) 46 (86.8%) 2 (100%) 177 (62.8%)
56
57
58
59
60 61
61 PCSS Mentoring Program PCSS Mentor Program is designed to offer general information to clinicians about evidence-based clinical practices in prescribing medications for opioid addiction. PCSS Mentors are a national network of providers with expertise in addictions, pain, evidence-based treatment including medicationassisted treatment. 3-tiered approach allows every mentor/mentee relationship to be unique and catered to the specific needs of the mentee. No cost. For more information visit: pcssnow.org/mentoring 62
62 PCSS Discussion Forum Have a clinical question? 63
63 Thank You! Please direct your comments, questions, and suggestions regarding future webinars to 64
64 PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with: American Academy of Family Physicians American Academy of Neurology Addiction Technology Transfer Center American Academy of Pain Medicine American Academy of Pediatrics American College of Emergency Physicians American College of Physicians American Dental Association American Medical Association American Osteopathic Academy of Addiction Medicine American Psychiatric Association American Society of Addiction Medicine American Society of Pain Management Nursing Association for Medical Education and Research in Substance Abuse International Nurses Society on Addictions American Psychiatric Nurses Association National Association of Community Health Centers National Association of Drug Court Professionals Southeastern Consortium for Substance Abuse Training 65
65 Educate. Train. Funding for this initiative was made possible (in part) by grant nos. 5U79TI and 3U79TI S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. 66
Main Results and Clinical Implications of the X:BOT Trial: XR-Naltrexone vs. Buprenorphine-Naloxone Film
Main Results and Clinical Implications of the X:BOT Trial: XR-Naltrexone vs. Buprenorphine-Naloxone Film July 31 st, 2018 Hosted by John A. Renner, Jr., MD, DLFAPA Professor of Psychiatry Boston University
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
Opioid Dependence 101 and Medication Assisted Treatment
Opioid Dependence 101 and Medication Assisted Treatment Dr. Joji Suzuki Director of the Division of Addiction Psychiatry, Brigham & Women s Hospital Assistant Professor of Psychiatry, Harvard Medical School
Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis
Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Sponsored by the Florida Alcohol and Drug Abuse Association
PCSS Projects. Kathryn L. Cates-Wessel Executive Director, AAAP PCSS-MAT and PCSS-O PI and Project Director
PCSS Projects Kathryn L. Cates-Wessel Executive Director, AAAP PCSS-MAT and PCSS-O PI and Project Director 1 Educational Objectives At the conclusion of this activity participants should be able to: Describe
Hospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
Methadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
Revised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
Medication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
The CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
Prepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good
PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion
THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
Appendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
Buprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
GOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
Treatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
Financing Factors for Implementing Medication-Assisted Treatment
Financing Factors for Implementing Medication-Assisted Treatment Jeremy Attermann, MSW, National Council for Behavioral Health Nick Szubiak, LCSW, National Council for Behavioral Health Brad DeCamp, MPA,
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
Medication Treatment and Opioid Use Disorder
Medication Treatment and Opioid Use Disorder Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBOT-B Boston Medical Center Disclosures I have no disclosures
Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
Pain Care & Prescription Drug Abuse: Current Topics, Legislation & Policy. Disclosure. Preview
Providers Clinical Support System for Opioid Therapies (PCSS-O) Webinar March 7, 2017 Pain Care & Prescription Drug Abuse: Current Topics, Legislation & Policy Wade Delk, Government Affairs Director, ASPMN
Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University
Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management Melissa Weimer, DO, MCR Oregon Health & Science University 1 Educational Objectives At the conclusion of this activity participants
OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL
OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial
6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
Opioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
Opioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
S 0332 S T A T E O F R H O D E I S L A N D
LC00 01 -- S 0 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO HEALTH AND SAFETY - COMPREHENSIVE DISCHARGE PLANNING Introduced By: Senators Miller,
SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018
GoToWebinar Housekeeping: Attendee participation
GoToWebinar Housekeeping: Attendee participation Your Participation Join audio: Choose Mic & Speakers to use your computer for audio. Not recommended for desktop units but works with laptops If not using
Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
Medication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
Management Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
Serious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder
An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder CONTENTS I. Need for an Alternative Payment Model for Opioid Use Disorder and Addiction... 2 A. Improving Services
Patient and Family Agreement on Opioids
Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of
Acute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
Addiction Prediction: Errors from the bedside hurt patients with pain. Objectives. CDC guideline for prescribing OPIOIDS for Chronic Pain
Addiction Prediction: Errors from the bedside hurt patients with pain Renee C.B. Manworren, PhD, APRN, BC, PCNS-BC, AP-PMN, FAAN Director of Nursing Research and Professional Practice Posy and Fred Love
Building capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
Opioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
Substitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
BUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder
BUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder Stephen A. Wyatt, DO Anthony Dekker, DO William Morrone, DO Funding for this initiative was made possible (in part) by Providers Clinical
Opioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
Management of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
Medication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
Health Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment
State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment DEPARTMENT OF HUMAN SERVICES (DHS) DIVISION OF MENTAL HEALTH & ADDICTION SERVICES (DMHAS) STORI INFORMATIONAL WEBINAR
Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
Medicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
Opioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
Methadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
S 2356 SUBSTITUTE A AS AMENDED ======== LC004564/SUB A/3 ======== S T A T E O F R H O D E I S L A N D
0 -- S SUBSTITUTE A AS AMENDED LC00/SUB A/ S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 0 A N A C T RELATING TO HEALTH AND SAFETY -- INSURANCE--MENTAL ILLNESS AND SUBSTANCE
MEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
Medication Assisted Treatment Georgia Statewide Conference September 12 th, 2016
Medication Assisted Treatment Georgia Statewide Conference September 12 th, 2016 Laurence M. Westreich, M.D. Associate Professor of Clinical Psychiatry Division of Alcoholism and Drug Abuse Department
Disclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
California. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
Methadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
MGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT
Bridging the Gap: Bridging the Gaps to addiction treatment through comprehensive collaborative practice among Advanced Practice Nurses in a large urban Medical Center Dawn Williamson, RN, DNP, PMHCNS-BC,
Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
Opioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
Aetna s Initiative on the Opioid Epidemic
Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than
2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC
SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a
Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting. October 25th, :00pm 3:00pm
Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting October 25th, 2017 2:00pm 3:00pm Webinar Login Directions Recommend calling in on your telephone. Enter your unique
2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
PTSD, Chronic Pain, and Opioid Use Disorder: A Case Discussion
PTSD, Chronic Pain, and Opioid Use Disorder: A Case Discussion Hosted by John A. Renner, Jr., MD, DLFAPA Professor of Psychiatry Boston University School of Medicine Director, Addiction Psychiatry Residency
Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 105- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum Learner Prep Objectives The purpose of this prep material
STARTING SUBOXONE IN PRIMARY CARE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to